Lipid Nanoparticle Encapsulating Beta-catenin siRNA ALN-BCAT

**Semantic type:** Pharmacologic Substance

**Definition:** A formulation consisting of lipid nanoparticle (LNP)-encapsulated small interfering ribonucleic acid (siRNA) targeting beta-catenin, with potential antineoplastic activity. Upon administration of LNP encapsulating beta-catenin siRNA ALN-BCAT, the LNP formulation delivers the siRNA particles to the tumor cells where the beta-catenin siRNA targets and binds to beta-catenin mRNA. This results in the inhibition of the translation and expression of beta-catenin. This disrupts beta-catenin-dependent oncogenic signaling and prevents the transcription of Wnt target genes that regulate the proliferation, migration, invasion, and the metastatic potential of tumor cells, as well as genes regulating the immunosuppression of the tumor microenvironment (TME). Dysregulation of the Wnt/beta-catenin signaling pathway is found in a variety of tumors and drives oncogenesis.

**Synonyms:** - ALN BCAT - ALN-BCAT - ALNBCAT - Beta-catenin-targeting RNA Interference Therapeutic ALN-BCAT - Beta-catenin-targeting RNAi Therapeutic ALN-BCAT - LNP Encapsulating Beta-catenin siRNA ALN-BCAT